ARTICLE | Clinical News
THV01-2: Phase I/II start
December 10, 2012 8:00 AM UTC
By year end, Theravectys will begin the double-blind, placebo-controlled, European Phase I/II THV01 trial to evaluate 3 dose levels of intramuscular THV01-1 followed by THV01-2 given 8 weeks apart in...